<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cromolyn (sodium cromoglicate) (oral inhalation): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cromolyn (sodium cromoglicate) (oral inhalation): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cromolyn (sodium cromoglicate) (oral inhalation): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="104683" href="/d/html/104683.html" rel="external">see "Cromolyn (sodium cromoglicate) (oral inhalation): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="104822" href="/d/html/104822.html" rel="external">see "Cromolyn (sodium cromoglicate) (oral inhalation): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52872023"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>PMS-Sodium Cromoglycate [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F44931509"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Mast Cell Stabilizer</li></ul></div>
<div class="block doa drugH1Div" id="F44931537"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6eaf0529-96af-46d7-a15e-d8e3d1ed0ca2">Asthma, maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, maintenance therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Routine use of cromolyn for asthma is not recommended due to lower efficacy relative to other therapies (GINA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization solution: Initial: 20 mg 4 times daily; must be used at regular intervals for 2 to 4 weeks to be effective. <b>Note:</b> Once control is achieved, may taper frequency gradually to the lowest effective dose (eg, 4 times daily, then 3 times daily).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f775c1c9-5151-4510-8960-10bea98d4f39">Exercise- or allergen-induced bronchospasm, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exercise- or allergen-induced bronchospasm,</b>
<b> prevention<b>:</b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Regular maintenance/controller therapy with inhaled corticosteroids or combination as-needed short-acting beta agonist and corticosteroid is preferred (GINA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization solution: 20 mg as a single dose; administer 10 to 15 minutes prior to exercise or allergen exposure.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991958"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F50989075"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doe drugH1Div" id="F44931538"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F44931536"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="104822" href="/d/html/104822.html" rel="external">see "Cromolyn (sodium cromoglicate) (oral inhalation): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6eaf0529-96af-46d7-a15e-d8e3d1ed0ca2">Asthma, maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, maintenance therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to lower efficacy relative to other therapies, current expert recommendations do not recommend cromolyn for either initial treatment of persistent asthma in children or routine use (GINA 2020; NAEPP 2007); cromolyn is considered an alternative medication for the treatment of mild persistent asthma in children (NAEPP 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Nebulization solution: Initial: 20 mg 4 times daily; usual dose: 20 mg 3 to 4 times daily; must be used at regular intervals for 2 to 4 weeks to be effective. <b>Note:</b> Once control is achieved, taper frequency to the lowest effective dose (eg, 4 times daily to 3 times daily to twice daily).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f775c1c9-5151-4510-8960-10bea98d4f39">Exercise- or allergen-induced bronchospasm, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b> Exercise- or allergen-induced bronchospasm, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Cromolyn may be considered for exercise-induced bronchospasm; however, regular controller therapy with inhaled corticosteroids or combination as-needed short-acting beta agonist and corticosteroids is preferred (AAAAI/ACAAI [Weiler 2016]; GINA 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents: Nebulization solution: 20 mg as a single dose; <b>Note:</b> Administer 10 to 15 minutes prior to exercise or allergen exposure but no longer than 1 hour before.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090056"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51090057"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block adr drugH1Div" id="F44931522"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Drowsiness</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Burning sensation of the nose, pruritus of nose</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea, stomach pain</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Serum sickness</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Cough (20%; transient), wheezing (4%; mild), epistaxis, nasal congestion, sneezing</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, anemia, angioedema, arthralgia, bronchospasm, dizziness, dysuria, exfoliative dermatitis, headache, hemoptysis, hoarseness, joint swelling, lacrimation, laryngeal edema, nephrosis, myalgia, parotid gland enlargement, pericarditis, peripheral neuritis, photodermatitis, polymyositis, pulmonary infiltrates (with eosinophilia), skin rash, urinary frequency, urticaria, vasculitis (periarteritis), vertigo</p></div>
<div class="block coi drugH1Div" id="F44931519"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cromolyn or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F44931520"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Anaphylaxis: Severe anaphylactic reactions may occur rarely</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Bronchospasm: May occur with cough after inhalation; if this occurs, treat with a fast-acting bronchodilator.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Asthma: Not to be used in the treatment of status asthmaticus.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Withdrawal: Caution should be used when withdrawing the drug or tapering the dose as symptoms may reoccur.</p></div>
<div class="block foc drugH1Div" id="F44931552"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nebulization Solution, Inhalation, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nebulization Solution, Inhalation, as sodium [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/2 mL (2 mL)</p></div>
<div class="block geq drugH1Div" id="F44931508"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F44931554"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Nebulization</b> (Cromolyn Sodium Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/2 mL (per mL): $2.50 - $10.85</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872024"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nebulization Solution, Inhalation, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/2 mL ([DSC])</p></div>
<div class="block adm drugH1Div" id="F44931542"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral inhalation: Nebulization solution: Squeeze contents of the unit-dose vial into the solution container of nebulizer. Nebulization should take approximately 5 to 10 minutes. Compatibility with other medications (eg, albuterol, budesonide) in nebulizer has been reported (Burchett 2010; Kamin 2014); also refer to institution-specific policies.</p></div>
<div class="block admp drugH1Div" id="F52614618"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral inhalation: Squeeze contents of the unit-dose vial into the solution container of nebulizer. Nebulization should take approximately 5 to 10 minutes. Compatibility with other medications (eg, albuterol, budesonide) in nebulizer has been reported (Burchett 2010; Kamin 2014); also refer to institution-specific policies.</p></div>
<div class="block use drugH1Div" id="F44931513"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma:</b> Maintenance and prophylactic therapy for asthma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Exercise- or allergen-induced bronchospasm, prevention:</b> Prevention of exercise- or allergen-induced bronchospasm.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although included as an FDA-approved use in the manufacturer’s prescribing information for the treatment of asthma, routine use is not recommended due to lower efficacy relative to other therapies (GINA 2023).</p></div>
<div class="block cyt drugH1Div" id="F44931568"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F44931565"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F44931517"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Limited data suggest little or no placental transfer (Brogden 1974).</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes). Maternal asthma symptoms should be monitored monthly during pregnancy (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than cromolyn are preferred for the control of asthma in pregnancy (GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes associated with asthma and the medications used to treat asthma in pregnancy is ongoing. Health care providers are encouraged to enroll exposed pregnant patients in the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (1-877-311-8972 or https://mothertobaby.org). Patients may also enroll themselves.</p></div>
<div class="block brc drugH1Div" id="F44931518"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if cromolyn is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends caution be used if administered to breastfeeding patients. The World Health Organization considers cromolyn to be compatible with breastfeeding (WHO 2002).</p></div>
<div class="block mop drugH1Div" id="F44931545"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">FEV<sub>1</sub>, peak flow meter and/or other pulmonary function tests; asthma symptoms.</p></div>
<div class="block pha drugH1Div" id="F44931526"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Prevents the mast cell release of histamine, leukotrienes, and slow-reacting substance of anaphylaxis by inhibiting degranulation after contact with antigens</p></div>
<div class="block phk drugH1Div" id="F44931528"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Inhalation: ~8% reaches lungs upon inhalation; well absorbed</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oral: &lt;1% of dose absorbed</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 80 to 90 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Inhalation: ~15 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Equally excreted unchanged in urine and feces (via bile); after inhalation, small amounts are exhaled</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-6418048">
<a name="6418048"></a>Ahmad S. Cromolyn Sodium and Anaphylaxis. <i>Ann Intern Med</i>. 1983;99:882. doi:10.7326/0003-4819-99-6-882_2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cromolyn-sodium-cromoglicate-oral-inhalation-drug-information/abstract-text/6418048/pubmed" id="6418048" target="_blank">6418048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4212341">
<a name="4212341"></a>Brogden RN, Speight TM, Avery GS. Sodium cromoglycate (cromolyn sodium): a review of its mode of action, pharmacology, therapeutic efficacy and use. <i>Drugs.</i> 1974;7(3):164-282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cromolyn-sodium-cromoglicate-oral-inhalation-drug-information/abstract-text/4212341/pubmed" id="4212341" target="_blank">4212341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20101066">
<a name="20101066"></a>Burchett DK, Darko W, Zahra J, Noviasky J, Probst L, Smith A. Mixing and compatibility guide for commonly used aerosolized medications. <i>Am J Health Syst Pharm</i>. 2010;67(3):227-230. doi:10.2146/ajhp080261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cromolyn-sodium-cromoglicate-oral-inhalation-drug-information/abstract-text/20101066/pubmed" id="20101066" target="_blank">20101066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cromolyn.1">
<a name="Cromolyn.1"></a>Cromolyn Sodium inhalation solution [prescribing information]. Locust Valley, NY: Fera Pharmaceuticals LLC; August 2020.</div>
</li>
<li>
<div class="reference">
                  Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. <i>Clinical Practice Guidelines</i>, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. <a href="http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm" target="_blank">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Updated 2020. Accessed May 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2">
<a name="GINA.2"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7799699">
<a name="7799699"></a>Hargreaves MR, Benson MK. Inhaled Sodium Cromoglycate in Angiotensin-Converting Enzyme Inhibitor Cough. <i>Lancet</i>. 1995;345(8941):13-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cromolyn-sodium-cromoglicate-oral-inhalation-drug-information/abstract-text/7799699/pubmed" id="7799699" target="_blank">7799699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24172851">
<a name="24172851"></a>Kamin W, Erdnüss F, Krämer I. Inhalation solutions--which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers--update 2013. <i>J Cyst Fibros</i>. 2014;13(3):243-250. doi:10.1016/j.jcf.2013.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cromolyn-sodium-cromoglicate-oral-inhalation-drug-information/abstract-text/24172851/pubmed" id="24172851" target="_blank">24172851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J.</i> 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cromolyn-sodium-cromoglicate-oral-inhalation-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href="http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf" target="_blank">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Accessed June 22, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27665489">
<a name="27665489"></a>Weiler JM, Brannan JD, Randolph CC, et al. Exercise-induced bronchoconstriction update-2016. <i>J Allergy Clin Immunol</i>. 2016;138(5):1292-1295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cromolyn-sodium-cromoglicate-oral-inhalation-drug-information/abstract-text/27665489/pubmed" id="27665489" target="_blank">27665489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li></ol></div><div id="topicVersionRevision">Topic 104680 Version 130.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
